George Hajjar, MD
Hematology & Oncology · Santa Clarita, CANPI 1619978715
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Amgen at 43.7% of the total. Reporting peaked in 2022 at $9,517 and has fallen 93.0% since, to $664 in 2025.
Across 112 payments — averaging $192.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$9K
- Athenex Pharmaceutical Division, LLC$4K
- AstraZeneca$4K
- Incyte Corporation$2K
- Daiichi Sankyo Inc.$650
- Merck$297
- plus $2K from 25 others
What the payments were for
- Consulting fees$6,02528%
- Speaking & faculty fees$12,49558%
- Grants$3502%
- Travel & lodging$3031%
- Food & beverage$2,07910%
- Education$3372%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 17 | $9,439 |
| Athenex Pharmaceutical Division, LLC | 3 | $3,850 |
| AstraZeneca(2 entities) | 12 | $3,559 |
| Incyte Corporation | 2 | $2,000 |
| Daiichi Sankyo Inc. | 1 | $650 |
| Merck | 5 | $297 |
| Pfizer | 15 | $222 |
| Sobi, Inc | 1 | $200 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $193 |
| E.r. Squibb & Sons, L.L.C. | 10 | $122 |
| Medtronic | 1 | $113 |
| Seagen Inc. | 6 | $104 |
| Cardinal Health 110 LLC | 1 | $100 |
| Intrinsiq Specialty Solutions, Inc. | 1 | $100 |
| Johnson & Johnson | 3 | $78 |
| Clovis Oncology, Inc. | 4 | $73 |
| Sanofi | 2 | $70 |
| Eisai Inc. | 4 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Puma Biotechnology, Inc. | 2 | $42 |
| Genentech USA, Inc. | 2 | $39 |
| Astellas Pharma US Inc | 2 | $36 |
| Gilead | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| EMD Serono, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Heron Therapeutics, Inc. | 1 | $19 |
| Novartis | 1 | $19 |
| EUSA Pharma (US) LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XGEVA$9,096
- Oral Paclitaxel$3,850
- Encequidar$3,850
- IMFINZI$1,050
- VANFLYTa$650
- CALQUENCE$640
- Truqap$525
- LYNPARZA$525
- KEYTRUDA$238
- Vonjo$200
- KYPHON Balloon Kyphoplasty$113
How this compares
$21,589 in reported general payments places this provider in the 75th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 29 | $409,240 |
| RevlimidLenalidomide | 24 | $405,247 |
| ErleadaApalutamide | 28 | $396,997 |
| VerzenioAbemaciclib | 14 | $205,924 |
| ImbruvicaIbrutinib | 13 | $201,049 |
| Everolimus | 12 | $96,774 |
| EliquisApixaban | 44 | $33,350 |
| Anastrozole | 54 | $1,337 |
| Ondansetron Hcl | 79 | $1,119 |
| Letrozole | 25 | $840 |
| Dexamethasone | 37 | $668 |
| Hydroxyurea | 30 | $561 |
| Bicalutamide | 21 | $454 |
| Acyclovir | 12 | $269 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $78 | $396,99728 claims |
| Lilly USA, LLCVerzenio | $15 | $205,92414 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $193 | $201,04913 claims |
| PfizerEliquis | $222 | $33,35044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Santa Clarita
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.